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Figure 
TDEs determine STAT3 activation, while TDSFs determine MDSC expansion. Bone marrow from naive mice was cultured 3 days in complete 
medium (CM) alone or with TCSs, TDEs, or TDSFs. (A) The percentage of Gr1+CD11b+ precursor cells ± SD was determined by flow cytometry. 
(B) The percentage of Ki67+ cells ± SD in Gr1+CD11b+ cells was determined by flow cytometry. (C) pStat3 MFI in Gr1+CD11b+ cells was deter-
mined by flow cytometry. Data represent MFI ± SD (n = 3); inset shows representative FACS histogram. (D) Purified splenic MDSCs from naive 
mice were treated with increasing dosages of TDEs. pStat3 expression was determined by FACS analysis. Data represent MFI ± SD (n = 3). (E) 
Activation of Stat3 and Erk in MDSC clones stimulated by TDEs or TDSFs was determined by Western blotting. (F) GM-CSF production by tumor 
cells was determined by ELISA. (G) Activation of Erk by TDSFs plus anti–GM-CSF blocking Ab was assessed by Western blotting. *P < 0.05.
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TDE-induced Stat3 activation determines MDSC suppressive functions. 
(A) Expression of pStat3 in MDSCs from naive and tumor-bearing mice 
(TB) was determined by Western blotting (upper panel) and FACS 
(lower panel). (B) CFSE-labeled OT-1 cells loaded with SIINFEKL 
and cultured alone or with MDSCs isolated from TB or naive mice 
at different MDSC/OT-1 ratios. Percentage of OT-1 proliferating cells 
was determined by flow cytometry (n = 3). (C) Peptide-loaded, CFSE-
labeled OT-1 cells were cultured alone or with MDSCs isolated from 
TB mice treated with PBS, JSI124, STA21, or Stat3 siRNA. CFSE dilu-
tion was determined by flow cytometry (n = 3). (D) Nude or WT mice 
were vaccinated or not with frozen/thawed CT26 cells 1 week before 
i.v. injection of CT26 cells admixed or not with MDSCs isolated from TB 
and previously treated with STA21 or Stat3 siRNA. 2 weeks later, lung 
metastasis numbers were evaluated (n = 5 mice per group). For box 
and whisker plots, bottoms and tops of boxes show the 25th and 75th 
percentiles, respectively, and middle bands show the median; whis-
kers show extrema. (E) Peptide-loaded, CFSE-labeled OT-1 cells were 
cultured alone or with bone marrow–derived MDSCs of naive mice 
previously treated alone or with tumor cell whole supernatant or TDE 
or TDSF fractions. CFSE dilution was determined by flow cytometry 
(n = 3 mice per group). (F) TB mice were injected or not with MDSCs. 
These MDSCs were either from TB or naive mice and stimulated with 
PBS, TDEs, or TDSFs. 2 days later, spleen cells were harvested and 
restimulated in vitro with CD3mAb+ dead tumor cells, then stained for 
intracellular CD4 and IFN-γ (upper panel) or CD8 IFN-γ (lower panel). 
*P < 0.05. Error bars represent mean + SD.
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Exosome depletion by DMA restores the efficacy of cyclophosphamide 
by inhibiting MDSC functions. Given that TDEs are responsible for 











































































TDEs trigger pStat3 expression in MDSCs through autocrine pro-
duction of IL-6. MDSCs from naive mice were treated with PBS or 
with TDSFs or TDEs. (A) IL-6 concentration in the supernatant was 
determined by ELISA. (B) In some wells, rIL-6 or blocking anti–IL-6 
mAb (aIL-6) were added. Data represent pStat3 MFI ± SD. (C) Naive 
mice were i.v. injected with PBS, EL4 TDEs, or rIL-6. EL4 TB mice 
were i.v. injected with PBS or IL-6 siRNA. 24 hours later, spleens were 
harvested. MDSC percentage (denoted) and pStat3 expression were 
determined by FACS on gated MDSCs. (D) EL4 cells were cultured 
in vitro for 24 hours and treated with PBS, DMA, or omeprazole. In 
vivo EL4 TB mice were injected daily with DMA for 1 week. Acetyl-
choline esterase activity was assayed in supernatant or sera. (E) IL-6 
concentration in sera was determined by ELISA in naive mice, which 
received a single injection of PBS or EL4 TDEs (left), or in EL4 TB 
mice, which received 1 daily injection of PBS, DMA, or omeprazole for 
1 week (right). (F) EL4 TB mice were injected with PBS alone or DMA, 
omeprazole, or IL-6 siRNA (si). Spleens were harvested 24 hours later, 
and pStat3 expression was determined by FACS. Data are shown as 
MFI ± SD. (G) Mice (n = 5) were vaccinated with frozen/thawed CT26 
cells 1 week before i.v. injection of live CT26 admixed or not with 
MDSCs isolated from PBS- or DMA-treated CT26 TB mice. Twelve 
days later, lung metastasis number was evaluated. Each experiment 
was done in triplicate. For box and whisker plots, bottoms and tops of 
boxes show the 25th and 75th percentiles, respectively, and middle 
bands show the median; whiskers show extrema. *P < 0.05.
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IL-6–induced pStat3 expression in MDSCs is dependent on the TLR2/MyD88 pathway. Purified MDSCs from WT or TLR2-, TLR4-, MyD88-, and 
Trif-deficient C57BL/6 tumor-free mice were cultured for 24 hours in complete medium supplemented or not with TDEs. IL-6 concentration in the 
supernatant was determined by ELISA (A), and pStat3 expression in cells was determined by FACS analysis (B). Data represent mean ± SD. 
(C) WT C57BL/6 mice or TLR2-, TLR4-, MyD88-, and Trif-deficient mice were s.c. injected with 1 × 106 EL4 cells. 3 weeks later, spleen cells were 
harvested, MDSC percentage was determined in spleen (denoted in left panels), and pStat3 expression was determined by FACS analysis on 
MDSC gated cells (right panel). (D) 2 × 105 OT-1 cells were labeled with CFSE, loaded with 10 μg/ml of SIINFEKL, and cultured 3 days alone or 
with different ratios of MDSCs from EL4 tumor-bearing WT mice or from EL4 tumor-bearing TLR2-deficient mice. Percentage of OT-1 proliferat-
ing cells was determined by flow cytometry. Each experiment was done in duplicate (n = 3 mice per group). (E) WT or TLR2–/– mice were injected 
s.c. with EL4 cells, and tumor growth was monitored. *P < 0.05.
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Hsp72 is expressed at the surface of TDEs and bound on TLR2. (A) Endogenous TLR2 ligand expression was investigated by immunoblots in 
TDEs, whole-cell lysates, and TDSFs from EL4, TS/A, and CT26 tumor cells. CTRL, control. (B) TDEs from EL4, TS/A, and CT26 tumor cells and 
exosomes from control 3T3 cells were coated on beads and labeled with control isotype or anti-Hsp72 or anti-Hsc73 Abs. Then FACS analysis 
was performed to determine expression of Hsp72 and Hsp73 at the surface of exosomes. One representative FACS histogram (blue line) is 
represented with its isotype control (pink area). (C) Surface plasmon resonance studying the binding of Hsp72 to TLR2 protein. FSL-1 (a bacte-
rial TLR2 ligand) was used as positive control; LPS was used as negative control. (D) Purified myeloid cells from naive WT or TLR2-deficient 
C57BL/6 mice were cultured in complete medium supplemented or not as indicated. pStat3 expression was determined by FACS analysis on 
MDSC gated cells. Data represent MFI ± SD. *P < 0.05.
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pStat3 expression in MDSCs is dependent on Hsp72 on TDEs. (A) Purified myeloid cells from naive WT or TLR2-deficient mice were either 
untreated or treated as indicated. (B) Naive mice were i.v. injected with TDEs from shRNA mock CT26 cells or Hsp72 shRNA CT26 clones H96 or 
H97. 18 hours later, spleen cells were harvested and pStat3 expression was determined by FACS. (C) Naive BALB/c mice were s.c. injected with 
1 × 106 H96, H97, or mock CT26 cells. 2 weeks later, spleens were harvested and pStat3 expression determined by FACS. For A–C, pStat3 was 
determined by FACS analysis on MDSC gated cells. Data represent MFI ± SD. Experiments were performed in triplicate (n = 3 mice per group). 
Inset shows immunoblot of pStat3 expression in sorted MDSCs from mice bearing mock CT26 or Hsp72 shRNA CT26 clone H96. (D) Mice were 
vaccinated with frozen/thawed CT26 cells 1 week before i.v. injection of live CT26 cells admixed or not with MDSCs isolated from mice bearing 
shRNA mock-transfected or Hsp72 shRNA-transfected (clone H96) CT26 tumors. Twelve days later, lung metastasis numbers were evaluated. 
Experiments were performed in triplicate (n = 5 mice per group). For box and whisker plots, bottoms and tops of boxes show the 25th and 75th 
percentiles, respectively, and middle bands show the median; whiskers show extrema. *P < 0.05. Error bars represent mean + SD.
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Exosome depletion restores the efficacy of immunotherapy. Immunocompetent mice (A) were injected s.c. with 1 × 106 CT26, TS/A, or EL4 cells. 
Mice were then either untreated or treated with 1 i.p. injection of 100 mg/kg cyclophosphamide (CTX), daily i.p. injection of DMA, or both. Mean 
tumor volume ± SD (n = 6 mice per group). (B) WT mice were injected as in A with CT26 and treated with intratumoral CpG 1668 injection (10 μg 
once a week) with or without DMA. (C) Nude mice were treated as in A. (D) BALB/c mice were injected s.c. with 1 × 106 CT26 cells. Mice were 
then either untreated or treated with 1 i.p. injection of cyclophosphamide or 1 i.p. injection of cyclophosphamide plus repeated daily i.p. injections 
of DMA with or without an i.v. adoptive transfer of 5 × 106 MDSCs from CT26 tumor-bearing mice. Data shown represent mean tumor volume ± SD 
(n = 5 mice per group). (E) BALB/c mice were injected s.c. with 1 × 106 mock-transfected (left panel) or Hsp72 shRNA–transfected (clone H96, 
middle panel; clone H97, right panel) CT26 cells. Mice were then either untreated or treated with 1 i.p. injection of cyclophosphamide, i.p. injection 
of DMA twice a week, or both. Mean tumor volume ± SD (n = 6 mice per group). Experiments were performed in duplicate. *P < 0.05.
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Generation of cells from bone marrow progenitors. Bone marrow cells were 
obtained from the femurs and tibias of WT mice. Five million bone mar-
Figure 
Exosomes produced by human cancer cell lines or meta-
static cancer patients dictate Stat3 activation in MDSCs and 
their immunosuppressive function through TLR2 and Hsp72. 
(A) The frequency of MDSCs, defined as HLA-DR CD33+ 
cells, is shown in the PBMCs of healthy volunteers (H.V.) 
(n = 11) and metastatic cancer patients (n = 18). Each plot 
is an individual measure, and the horizontal bar is the mean. 
(B) Immunosuppressive function of MDSCs from peripheral 
blood of healthy volunteers and metastatic cancer patients 
on stimulated T cell proliferation. T cell stimulation was 
induced by a mixture of anti-CD2, anti-CD3, and anti-CD28 
beads (n = 10). (C) PBMCs from healthy volunteers were 
cultured for 24 hours in medium alone or medium containing 
TDEs from H23 cells with or without blocking TLR2 Abs or 
anti-Hsp72 polyclonal Abs (pAbs). pStat3 was determined 
by flow cytometry on MDSC gated cells (n = 10). (D) Immu-
nosuppressive function of MDSCs from blood of healthy 
volunteers either untreated or treated with TDEs from H23 
cells alone or with blocking TLR2 Abs or anti-Hsp72 pAbs 
(n = 8). (E) PBMCs from metastatic cancer patients were 
incubated overnight in serum-free medium supplemented 
with autologous serum or PBS. pStat3 expression in gated 
MDSC was determined by flow cytometry. pStat3 MFI ratio 
between PBS and serum condition was represented. The 
same patients were sampled before and after 3 weeks of 
amiloride treatment (n = 11). (F) Immunosuppressive func-
tion of MDSCs prepared from peripheral blood of metastatic 
cancer patients, treated with amiloride or not treated, on T 
cell proliferation stimulated as in B. *P < 0.05. Error bars 
represent mean + SD.
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Exosome  preparations  were  stained  with  osmium  tetroxide,  then 
observed with a Hitachi H-7500 electronic microscope equipped with 
an AMT camera.
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